Ophthalmologic Drug Guide
Buch in deiner Nähe kaufen
Beschreibung
The updated edition of this popular pocket guide includes new drugs available and FDA-approved since publication of the first edition and also guidance on using the growing number of drugs now prescribed for off-label purposes, such as anti-VEGF agents, used in cancer treatments, which are also being used to stop cell growth in age-related macular degeneration. Drugs are grouped by presenting disease (e.g., glaucoma, retinal disease, cataracts), and readers may also access information via the Product Index or the Subject Index. The entire book is presented in a table format to facilitate quick look-up.
Drug therapy as an alternative to surgical intervention is becoming increasingly common. In the past five years, new anti-glaucoma agents have becoming increasingly effective. This edition will include new information on off-label prescribing and cap colors where they are mandated by the FDA (pink/white for steroid drops, grey for topical NSAIDS, etc.);There are now several new pharmaceutical agents being used to treat retinal diseases such as age-related macular degeneration (Macugen, Lucentis, Visudyne), while other drugs formerly prescribed have now been shown to be less effective. Intraocular infections are primarily treated with intravitreal medications. Additionally, the anti-allergy and dry eye markets continue to grow, with a new formulation of Allergan's Acular 0.5% (ketorolac tromethamine) and Elestat ophthalmic solution, its new antihistamine-mast cell stabilizer.
All-inclusive formulary for ocular prescription medications Three ways to access drug information: by disease, by product name, and by topic Presented in table format, to facilitate quick look-up New edition includes new agents in retinal disease and glaucoma Includes supplementary material: sn.pub/extras
to follow
Autor*in
Douglas J. Rhee
Themen in »Ophthalmologic Drug Guide«
formulary macular ophthalmology optometry pharmacologic therapy retina